Athe serves as the protocol virologist for A5336, a randomized pilot study of ruxolitinib in antiretroviral-treated HIV-infected adults, and A5366, a study of tamoxifen’s ability to enhance the efficacy of viral reactivation with histone deacetylase inhibitors. He also is the principal investigator of a new project that explores the effects of obesity on HIV-1 reservoir decay during antiretroviral treatment initiation.